HomeIMM • ASX
add
Immutep Ltd
Nakaraang pagsara
$0.32
Sakop ng araw
$0.32 - $0.33
Sakop ng taon
$0.23 - $0.46
Market cap
487.96M AUD
Average na Volume
3.88M
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Mga balita tungkol sa merkado
Mga Financial
Income Statement
Kita
Net na kita
| (AUD) | Hun 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | 865.57K | -4.89% |
Gastos sa pagpapatakbo | 2.03M | -10.92% |
Net na kita | -10.74M | -11.49% |
Net profit margin | -1.24K | -17.23% |
Kita sa bawat share | — | — |
EBITDA | -11.21M | -17.52% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (AUD) | Hun 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 181.88M | 47.37% |
Kabuuang asset | 201.58M | 36.71% |
Kabuuang sagutin | 12.06M | 9.82% |
Kabuuang equity | 189.52M | — |
Natitirang share | 1.45B | — |
Presyo para makapag-book | 2.46 | — |
Return on assets | -14.53% | — |
Return on capital | -15.32% | — |
Cash Flow
Net change in cash
| (AUD) | Hun 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -10.74M | -11.49% |
Cash mula sa mga operasyon | -8.19M | 30.16% |
Cash mula sa pag-invest | -10.30M | -87,445.92% |
Cash mula sa financing | 47.81M | 25.58% |
Net change in cash | 29.03M | 5.47% |
Malayang cash flow | -6.10M | -44.31% |
Tungkol
Immutep Ltd is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine. In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.
Prima currently has three main products in its pipeline, all acquired with Immutep:
Eftilagimod alpha, which is recombinant soluble LAG-3, used as an activator of antigen presenting cells. This product has completed a Phase IIa clinical study, where it doubled the expected response rate in HER2-negative metastatic breast cancer.
IMP731, a depleting monoclonal antibody for autoimmune diseases, targeting LAG-3+ activated T cells. This antibody has been licensed to GlaxoSmithKline.
IMP701, an antagonist monoclonal antibody to LAG3 for use in cancer. This product has been licensed to Novartis Wikipedia
CEO
Itinatag
2001
Website
Mga Empleyado
19
